Notus Mucolítico (Carbocisteine)

Carbocisteine is used as a mucolytic agent to facilitate mucus clearance in respiratory disorders.

• Chronic obstructive pulmonary disease (COPD): improves sputum clearance and reduces cough frequency.
• Acute and chronic bronchitis: thins bronchial secretions to aid expectoration.
• Productive cough with thick sputum: decreases viscosity of mucus, making it easier to expel.

• Carbocisteine acts by cleaving disulfide bonds within mucoproteins, which reduces the molecular weight and viscosity of mucus. The resulting thinner secretions are more easily transported by ciliary action and cough, enhancing clearance from the airways. This mucolytic effect helps to relieve airway obstruction and improve ventilation in patients with excessive or thickened sputum. By improving mucus rheology, carbocisteine also supports the host’s innate defense mechanisms against respiratory infections.

Carbocisteine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Nausea: mild stomach upset.
• Diarrhea: loose stools.
• Headache: mild to moderate headache.

Serious or Rare Side Effects

• Allergic reactions: rash, urticaria, or angioedema.
• Bronchospasm: sudden airway tightening.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing carbocisteine, clinicians should consider several precautionary measures to ensure safe use.

• Renal function assessment: adjust use in patients with severe renal impairment.
• Hepatic monitoring: observe liver function tests during prolonged therapy.
• Asthma caution: avoid in patients with a history of bronchial hyperreactivity.
• Hypersensitivity check: do not use if known allergy to carbocisteine or excipients.
• Elderly dosage: consider lower doses for older adults due to altered pharmacokinetics.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Carbocisteine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concomitant antitussives containing codeine: may counteract mucolytic effect.
• Other mucolytics (e.g., N‑acetylcysteine): risk of excessive mucus thinning.
• Strong oxidizing agents: chemical incompatibility leading to degradation.

Moderate Interactions (Monitor Closely)

• Macrolide antibiotics (e.g., azithromycin): may increase gastrointestinal upset.
• Anticoagulants (e.g., warfarin): rare reports of enhanced bleeding risk.
• ACE inhibitors: possible increase in cough severity.